Subsequently, the Oncomine and the OncoLnc database were employed to verify the differential expression and the association with clinical outcome of SGK1 gene in breast cancer patients.
β2M has a different molecular regulatory mechanism between ER<sup>+</sup> and ER<sup>-</sup> breast cancer with HER2<sup>-</sup>, and it may promote tumor survival through the SGK1/Bcl-2 signaling pathway in ER<sup>+</sup> breast cancer with HER2<sup>-</sup> and has no regulatory effects on ER<sup>-</sup> breast cancer with HER2<sup>-</sup>.
We have aimed to demonstrate the impact of TGF-β1 and fluvastatin on human breast cancer (MCF-7) and human hepatocellular carcinoma (Hep3B) cell cultures via Real-Time Cell Analyzer (RTCA) and to test the expression levels of some genes (NDRG1, SGK1, TWIST1, AMPKA2) and to compare their gene expression levels according to RTCA results.
SGK1 may act as a downstream intracellular regulator of c-fms, particularly of c-fms-induced adhesiveness of breast cancer cells after exposure to GC or CSF-1.